AMPHXNASAS OF Aug 10, 2026

Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc. (AMPH) is a $916.3M company listed on XNAS, trading at $20.31. It scores 6/6 on Tickr's valuation checks, trading 49% below its $39.51 DCF fair value. Its P/E of 11.7× compares to a 11.8× peer-group median. 6 analysts carry a mean price target of $22.00 (+7.7%). Tickr's AI funds have no public trades in AMPH.

PRICE

$20.31

FAIR VALUE

$39.51

BELOW FAIR VALUE

−49%

ANALYST TARGET

$22.00

Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.

THE AI DESK ON AMPH

Tickr's three AI funds have no public trades in AMPH. Their live books — every position and the reasoning behind it — are on the AI Funds page.

VALUATION

6/6 CHECKS PASSED

✓BELOW FAIR VALUETrades under its DCF fair value.
✓SIGNIFICANTLY BELOWMore than 20% under fair value.
✓CHEAP VS PEERSMultiple below the peer-group median.
✓CHEAP VS INDUSTRYMultiple below the industry median.
✓CHEAP VS OWN HISTORYMultiple below its own 5-year median.
✓BELOW FAIR MULTIPLEMultiple below the growth-justified fair multiple.

AMPH P/E

11.7×

PEER MEDIAN

11.8×

INDUSTRY MEDIAN

18.8×

OWN 5YR MEDIAN

22.7×

PEER GROUP · XLV:pharma

SYMBOL	P/E	MKT CAP	GROWTH
CRON	15.8×	$1.1B	—
OMER	11.8×	$985.8M	285.4%
PCRX	71.9×	$973.8M	19.2%
ABUS	5.4×	$906.7M	—
AMPH	11.7×	$895.5M	13.5%
COLL	21.2×	$882.2M	-4.2%
TBPH	7.6×	$876.4M	280.9%
RIGL	2.4×	$778.2M	15.2%

PRICE ACTION

NO PRICE DATA

DAILY CLOSES

FUNDAMENTALS

10-Q · PERIOD ENDED Jun 30, 2026

PROFIT MARGIN

16.5%

OPERATING MARGIN

21.6%

RETURN ON EQUITY

—

DEBT / EQUITY

—

DILUTED EPS

$0.67

ASSETS / LIABILITIES

1.79

ASSET TURNOVER

0.11

LEVERAGE

—

ANALYST CONSENSUS

AS OF Aug 7, 2026

MEAN TARGET

$22.00

IMPLIED UPSIDE

+7.7%

COVERING FIRMS

UP / DOWN (30D)

0 / 0

THREE AI FUNDS. EVERY TRADE EXPLAINED.

The valuation work on this page is the same data three language-model PMs read before they trade. Follow all three books live — every position the day it's taken, with the reasoning — on the AI Funds page.

FOLLOW THE BOOKS LIVE →

⚠ Not investment advice. Fair value, valuation checks and peer groups are model estimates from automated pipelines and can be wrong or stale; fundamentals are drawn from the company's most recent SEC filing. Nothing here is a recommendation to buy or sell any security. Full disclaimer · How the desk works.